LLAI - Ticker AI Digest

LungLife AI Inc 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
LungLife AI Inc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
LLAI Data 2025-04-29 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (LLAI) 1
LLAI 06:01
LungLife AI Inc
Notice of Special Meeting
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
LLAI 06:01
LungLife AI Inc
License Agreement and Other Matters
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
LungLife AI, a developer of clinical diagnostic solutions for lung cancer, has entered into an exclusive license and distribution agreement with Circulogene Theranostics, a US liquid biopsy diagnostics company. The agreement grants Circulogene the exclusive rights to improve, develop, market, and sell LungLifes LungLB® <mark style="background-color:yellow">test</mark> in the US, along with its software and intellectual property. LungLife will receive an advanced payment of $375,000, followed by a second payment of the same amount upon completion of the agreement. LungLife will also receive royalty payments of 20% of net revenue collected by Circulogene for the first year, with a minimum guaranteed amount. The agreement includes an asset purchase option for Circulogene to acquire LungLifes licensed IP and equipment for $6.2 million. LungLifes CEO, Paul Pagano, expresses enthusiasm for the partnership, while Circulogenes CEO, Mike Mullen, highlights the potential impact of LungLB® on lung cancer detection. The agreement is expected to reduce LungLifes operating activity, leading to a proposed cancellation of its admission to trading on AIM, with shareholder approval to be sought.
Agreement
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 2
LLAI 06:01
LungLife AI Inc
Notice of Special Meeting
LLAI 06:01
LungLife AI Inc
License Agreement and Other Matters
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
LungLife AI, a developer of clinical diagnostic solutions for lung cancer, has entered into an exclusive license and distribution agreement with Circulogene Theranostics, a US liquid biopsy diagnostics company. The agreement grants Circulogene the exclusive rights to improve, develop, market, and sell LungLifes LungLB® <mark style="background-color:yellow">test</mark> in the US, along with its software and intellectual property. LungLife will receive an advanced payment of $375,000, followed by a second payment of the same amount upon completion of the agreement. LungLife will also receive royalty payments of 20% of net revenue collected by Circulogene for the first year, with a minimum guaranteed amount. The agreement includes an asset purchase option for Circulogene to acquire LungLifes licensed IP and equipment for $6.2 million. LungLifes CEO, Paul Pagano, expresses enthusiasm for the partnership, while Circulogenes CEO, Mike Mullen, highlights the potential impact of LungLB® on lung cancer detection. The agreement is expected to reduce LungLifes operating activity, leading to a proposed cancellation of its admission to trading on AIM, with shareholder approval to be sought.
Agreement

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for LLAI.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2025-04-29 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
LungLife AI Inc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
06:01 Today's Catalyst Notice of Special Meeting
Single-Ticker Today's AI
LLAI signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for LungLife AI Inc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full LLAI Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for LLAI on 2025-04-29.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
1.3M
Enterprise Value
20.3M
Public Float
37.0
Broker Target
171
Shares Out
30.7M
Long Interest
0
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
USU5500L1045
Market
-
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for LLAI.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2025-04-29 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
LungLife AI Inc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
06:01 Today's Alert Notice of Special Meeting
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
-
Earnings Date
-
Net Debt
-2.4M
Cash
2.7M
EPS
-0.12
Net Income
-5.4M
Revenue
29.0K
Enterprise Value
20.3M
Trailing PE
-
Forward PE
-
Price Sales TTM
44.9308
Price Book MRQ
0.2167
EV Revenue
564.0165
EV EBITDA
-1.8632
Financial Forecastist

Worsening financial engine

Revenue is slipping -73.9% against the prior comparable period. Net margin is compressing by 18,812.3 pts. Net debt is building +13.9%.

Revenue -73.9% Net Income -33.7% FCF -27.9% Current Ratio 2.83x Forward Rev 0
Worsening
Quarter Revenue
6.0K
-73.9%
vs prior comparable quarter
Net Margin
-31016.7%
-18812.3 pts
profitability pulse
Free Cash Flow
-1.9M
-27.9%
cash conversion
Net Debt / EBITDA
1.4x
+13.9%
lower is cleaner
Revenue Engine

Latest quarter printed 6.0K with the top line cooling off against the last comparable period.

Profit Stack

Net income landed at -1.9M and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 2.6M while net debt is -2.4M. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q2 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2025
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2024
Consensus
4.0M
Revenue Path
-0.13
EPS / Earnings
Growth cue +0.2%
FY 2025
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue +1.0%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q2 2024 6.0K -1.9M -1.9M -2.4M
Q1 2024 3.0K -930.5K -974.5K -2.6M
Q4 2023 23.0K -2.6M -2.4M -2.4M
Q3 2023 11.5K -1.3M -1.2M -2.6M
Q2 2023 23.0K -2.8M -2.7M -2.1M
Q1 2023 11.5K -1.4M -1.4M -2.4M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2023 46.0K -5.4M -5.1M -5.1M
FY 2022 24.0K -7.6M -7.3M -5.9M
FY 2021 195.6K -7.4M -6.7M -9.4M
FY 2020 205.2K -5.6M -3.8M -2.9M
FY 2019 136.5K -4.7M -3.1M -3.4M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend broken

Price is -49.5% through the 52-week range, -81.7% vs 50DMA and -93.7% vs 200DMA. 100.0% of the register is locked by institutions and insiders, leaving 0.0% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend broken Institutional gravity Moderate income rhythm As Of 2026-04-19
Balanced Structure
Structure Score
38.6 / 100
Balanced Structure
Trend Stack
-81.7% / -93.7%
vs 50DMA / 200DMA
52W Position
-49.5%
auction position inside the yearly range
Ownership Lock
100.0%
53.8% institutions | 50.6% insiders
Pressure Pocket
0.0% free float
Vendor short-float fields were not supplied
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 0.43 with the stock -81.7% vs 50DMA and -93.7% vs 200DMA. The tape is sitting -49.5% through the 52-week range, which frames the regime as trend broken.

Ownership Register

Institutions hold about 53.8% and insiders about 50.6%, locking roughly 100.0% of the register and leaving 0.0% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
0.43
derived from market cap / shares
52W High
5.00
upper auction edge
52W Low
1.94
lower auction edge
Beta
0.37
volatility character
Shares Out
30.7M
fully diluted count
Shares Float
11.3M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
17.64
Institutions As Of
2025-05-27
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for LLAI, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2025-04-29 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
LungLife AI Inc has fresh news flow live now, so the tape is framing the chart workspace below.
06:01 Today's Catalyst Notice of Special Meeting
AI Charts Studio
LLAI Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-04-29 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast